PLASMACHEM PRODUKTIONS- UND HANDEL GMBH

Their core work

PlasmaChem is a Berlin-based SME that produces and supplies advanced nanomaterials, nanoparticles, and surface coatings for industrial and biomedical applications. They specialize in manufacturing functional nanocomposites — from metallic coatings on textiles to biocompatible materials for tissue engineering and drug delivery. Their core business is translating nanomaterial chemistry into application-ready products, serving as a materials supplier and process partner within European R&D consortia. They bridge the gap between laboratory-scale nanomaterial synthesis and industrial-scale production.

What they specialise in

How they've shifted over time

In their early H2020 period (2016–2018), PlasmaChem focused on traditional materials characterisation and industrial coatings — surface adhesion testing, nanoindentation, AFM modelling, and textile metallisation. From 2019 onward, their work shifted decisively toward biomedical and responsive materials: ultrasound-triggered nanocomposites for tissue treatment, handheld bioprinting substrates, and colloidal cybernetic systems with memory-like properties. This evolution shows a company moving from passive functional materials toward active, stimuli-responsive, and biologically integrated nanomaterial systems.

PlasmaChem is pivoting from conventional nanomaterial supply toward smart, biologically active materials — expect future work at the intersection of nanotechnology and biomedical engineering.

How they like to work

PlasmaChem operates predominantly as a specialist partner (4 of 5 projects), contributing nanomaterial production expertise to larger consortia rather than leading them. Their single coordination was a small SME Instrument Phase 1 project (EUR 50K), suggesting they use that scheme for internal innovation while joining larger RIA/IA consortia as a materials supplier. With 45 unique partners across 15 countries, they maintain a broad European network — characteristic of a niche SME that is sought after by diverse research teams needing reliable nanomaterial components.

PlasmaChem has collaborated with 45 distinct partners across 15 countries, indicating a wide but not deep network — they rarely repeat partners, instead serving as a go-to nanomaterial supplier that different consortia recruit for specific material needs.

What sets them apart

PlasmaChem occupies a rare niche as a production-capable nanomaterial SME that can both manufacture and co-develop application-specific nanoparticles and coatings. Unlike university labs that produce nanomaterials at bench scale, PlasmaChem offers industrial production capacity combined with R&D flexibility — making them valuable for projects that need to move beyond proof-of-concept. Their recent pivot into biomedical responsive materials adds a distinctive capability that few small-scale nanomaterial producers can match.

Highlights from their portfolio

• ADMAIORA
  Largest funding (EUR 347K) and most technically ambitious — combining nanocomposites, ultrasound-triggered drug release, and handheld bioprinting for osteoarthritis treatment.
• COgITOR
  Their most recent and forward-looking project (EUR 307K), exploring colloidal cybernetic systems with memory properties — signals their future research direction.
• TINOHEAT
  Their only coordinated project, an SME Instrument Phase 1 exploring novel heating for plastic packaging — shows internal innovation ambition beyond partner roles.